Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.
Xiao Jun WangYi-Ho WangShing Chau Tony LiChristina GkitziaSoon Thye LimLiang Piu KohFrancesca Lorraine Wei Inng LimWilliam Ying Khee HwangPublished in: Journal of medical economics (2021)
TIS for treating r/r DLBCL patients who have failed ≥2 lines of systemic therapies, is likely to be cost effective with limited budget impact.